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OBJECTIVE
Continuous glucose monitoring (CGM) is increasingly used to assess glucose con-
trol in diabetes. The objective was to examine how analysis of glucose data might
improve our understanding of the role temporal glucose variation has on large-
for-gestational-age (LGA) infants born to women with diabetes.
RESEARCH DESIGN AND METHODS
Functional data analysis (FDA) was applied to 1.68 million glucose measurements
from 759 measurement episodes, obtained from two previously published ran-
domized controlled trials of CGM in pregnant women with diabetes. A total of 117
women with type 1 diabetes (n = 89) and type 2 diabetes (n = 28) who used
repeated CGM during pregnancy were recruited from secondary care multidisci-
plinary obstetric clinics for diabetes in the U.K. and Denmark. LGA was deﬁned as
birth weight ‡90th percentile adjusted for sex and gestational age.
RESULTS
A total of 54 of 117 (46%) women developed LGA. LGA was associated with lower
mean glucose (7.0 vs. 7.1 mmol/L; P < 0.01) in trimester 1, with higher mean
glucose in trimester 2 (7.0 vs. 6.7 mmol/L; P < 0.001) and trimester 3 (6.5 vs.
6.4 mmol/L; P < 0.01). FDA showed that glucose was signiﬁcantly lower midmorn-
ing (0900–1100 h) and early evening (1900–2130 h) in trimester 1, signiﬁcantly
higher early morning (0330–0630 h) and throughout the afternoon (1130–1700 h)
in trimester 2, and signiﬁcantly higher during the evening (2030–2330 h) in tri-
mester 3 in women whose infants were LGA.
CONCLUSIONS
FDA of CGM data identiﬁed speciﬁc times of day that maternal glucose excursions
were associated with LGA. It highlights trimester-speciﬁc differences, allowing
treatment to be targeted to gestational glucose patterns.
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Globally, diabetes affects up to 12% of
all pregnancies (1), and the proportion
of pregnancies affected is increasing (2).
Among women with pregestational
(type 1 or 2) diabetes, macrosomia, or
large for gestational age (LGA), is the
commonest complication of pregnancy,
affecting one in two infants (3–8). As
well as the adverse obstetric (labor com-
plications, perineal tearing, instrumen-
tal delivery, and caesarean section)
and perinatal (shoulder dystocia, respi-
ratory distress, neonatal hypoglycemia,
and stillbirth) outcomes associated with
LGA, LGA infants are themselves at in-
creased risk of developing obesity, dia-
betes, and cardiovascular disease in
later life (9–13).
Maternal hyperglycemia has long been
considered the principal determinant of
LGA and the factor most amenable to in-
tervention (14,15). However, the preva-
lence of LGA remains high even in
diabetic pregnancies that are considered
clinically “well controlled” where self-
monitored capillary blood glucose
(SMBG) or HbA1cmeasurements indicate
that clinical management has been suc-
cessful in normalizing maternal glucose
levels (4–6,16). This suggests either that
something other than glucose levels is
responsible for LGA in these women or
that SMBG and HbA1c measurements fail
to detect the variation in glucose levels
that is capable of causing LGA.
This has led to substantial interest in
the potential role that continuous glu-
cosemonitoring (CGM)might play in im-
proving the clinical assessment and
management of glycemic control. None-
theless, the sheer volume of data these
devices produce (288 glucose measure-
ments per day) and the complexity of
the underlying signals these data con-
tain mean that CGM data have proved
challenging to analyze and interpret. To
address this, some analysts have recom-
mended using a wide range of summary
statistical indices (such as calculating av-
erage glucose levels over speciﬁed time
periods or measuring the time above,
below, or within a speciﬁed target)
(17). Unfortunately, all of these indices
removemuch of the potential additional
information that such temporal data of-
fer. This includes not only an indication
of glucose levels at or across speciﬁc
points in time but also measures of
change (or velocity), rate of change (or
acceleration), and variability. Accessing
this additional information, and making
it available for clinical interpretation
and application, requires more sensitive
statistical techniques. Functional data
analysis (FDA) is one such technique, be-
ing capable of summarizing temporal
trends in continuously recorded mea-
surements in a form that is amenable
to subsequent multivariable statistical
analysis. The aim of the current study
was therefore to examine the extent to
which summary statistical indices and
FDA of CGM data might improve our un-
derstanding of the role that residual var-
iation in glucose levels might play in the
development of LGA infants in clinically
well-controlled diabetic pregnancies.
RESEARCH DESIGN AND METHODS
This multicenter study drew on data
from two studies: one based in England
(East Anglia) and the second in Denmark
(Copenhagen) (16,18). Both studies re-
cruited pregnant women with pregesta-
tional type 1 or type 2 diabetes to
prospective, randomized controlled trials
that explored the clinical impact of CGM
on maternal, fetal, and neonatal health
outcomes. All participants were treated
with insulin either before pregnancy or
as soon as pregnancy was conﬁrmed.
In England, pregnant participants,
aged 16–45 years, were recruited in
two secondary care diabetes antenatal
clinics between 2003 and 2006. In Den-
mark, pregnant participants, aged 19–43
years, were recruited from one diabetes
antenatal clinic between 2009 and 2011.
Full details of clinical recruitment proce-
dures (including the exclusion of partici-
pants with severe medical or psychological
comorbidities) have been described pre-
viously (16,18).
Antenatal and Perinatal Care
All participants received routine clinical
care as per national guidelines. In Eng-
land, this involved antenatal clinic visits
every 2–4 weeks, four to six of which
included additional study-related as-
sessments. In Denmark, antenatal clinic
visits occurred every 2 weeks, with ﬁve
study visits undertaken at 8, 12, 21, 27,
and 33 weeks gestation. Both studies
used comparable glucose targets: in
England ,5.5 mmol/L before meals,
,7.8 mmol/L at 60 min, and ,6.7
mmol/L at 120 min postmeals; and in
Denmark 4.0–6.0 mmol/L before meals,
4.0–8.0mmol/L at 90min postmeal, and
6.0–8.0 mmol/L before bed.
Antenatal records provideddata on the
following: maternal BMI, HbA1c levels,
age at onset of diabetes, type of diabetes,
insulin regimen (i.e., via pump ormultiple
daily injections), infant sex, birth weight,
and gestational age at birth. The latter
were used to deﬁne LGA as a birth weight
on or above the 90th percentile for sex-
and gestation-adjusted birth weight ac-
cording to British (19) and Scandinavian
(20) growth references.
CGM
Continuous glucose monitors were used
to record electrochemically measured
subcutaneous interstitial glucose concen-
trations every 5 min, generating 288 mea-
surements per day. Both studies used
Medtronic CGM systems (Medtronic-
MiniMed, Northridge, CA), with CGM-
Gold sensors used in England and
Guardian Real-Time CGMwith Sof-Sensors
in Denmark. Monitors were calibrated
against capillary blood glucose measure-
ments as per the manufacturer’s instruc-
tions. To make full use of the temporal
information provided by the multiple
measures of glucose recorded by CGM,
data collected from each participant
over a series of days were taken to
constitute a measurement episode. In
England, these episodes constituted the
length of time that each sensor was
worn (5–7 days). In Denmark, these mea-
surement episodes comprised separate
weeks. Based on the volume of CGM
data available, our analyses have 98%
power at the 5% level to detect a
1 mmol/L difference in glucose between
participants who delivered infants with
or without LGA.
Summary Statistical Analysis
To facilitate comparisons between the
CGM data examined in this and previous
studies, we calculated a range of sum-
mary statistical indices including the fol-
lowing: mean CGM glucose levels; the
percentage of time spent within the di-
abetes pregnancy glucose target range
(3.5–7.8 mmol/L); and the area under
the curve (a measure of participant ex-
posure to high, low, and normal glucose
levels over time) for all glucose mea-
surements that exceeded thresholds of
7.8 or 6.7 mmol/L, or fell below thresh-
olds of 3.5 or 2.8 mmol/L (17,21). Mea-
sures of glycemic variability were also
calculated (22), including the following:
SD of mean CGM glucose levels, which
shows howmuch variation there is from
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the average; M-value (23), which is a
measure of variability, calculated
using a formula from each glucose value,
and then divided by the total number of
glucose values to produce amean;mean
amplitude of (positive + and negative2)
glycemic excursions (MAGE+/2), which
summarizes glycemic variability by iden-
tifying glucose peaks and troughs whose
amplitudes lie .1 SD outside of the
mean (24); lability index (LI), which is a
score based on the change in glucose
levels over time (25); J-index, which is
calculated using mean glucose levels
and their SD (26); average daily risk ratio
(ADRR), which is calculated by trans-
forming each glucose value and then at-
tributing risk to the transformed point
so that it is possible to generate the risk
attributed to low glucose (RLBG) and
high glucose (RHBG) (27); glycemic risk
assessment in diabetes equation (GRADE),
which summarizes the degree of risk asso-
ciated with variability in glucose proﬁle (a
score of ,5 indicates well-controlled glu-
cose proﬁles in the nondiabetic range
and a score of .5 indicates periods of
clinically signiﬁcant hypo or hyperglycemia
[28]); and mean absolute glucose (MAG),
which calculates the sum of differences
between successive glucose values divided
by the total time over which these values
are recorded (29).
FDA
Each of the glucose measurements re-
corded during each of themeasurement
episodes was assumed to be dependent
upon (rather than independent of) the
preceding glucose levels. Changes in
glucose over time were therefore as-
sumed to be progressivedoccurring
in a trend or sequence that could be
considered “smooth” (in a mathemati-
cal sense) without step changes from
one measurement to the next. For this
reason, sequential glucose measure-
ments from each measurement episode
were modeled as trajectories by calculat-
ing continuousmathematical functions of
CGM-derived glucose measurements col-
lected every 5 min throughout that mea-
surement episode. These trajectories
were modeled using the technique of ﬁt-
ting B splines to the repeated measures
(30). This technique generates a poly-
nomial function that describes the curve
(or “spline”) used to model changes in
glucose levels over time for each partici-
pant, with splines required to pass through
measured glucose values at discrete time
points (called “knots”) during each 24-h
period. At each of these knots, the spline
function was required to be continuous
(i.e.,withnobreaks or step changes) so that
the function remained mathematically
smooth. Knots were placed at 120-min
intervals over each 24-h measurement
period, with data from measurements re-
corded during the 4 h either side of mid-
night (i.e., from2000 to0400h) repeatedat
the beginning and end to eliminate arti-
factual edge effects. In this way, the
splines provided a smooth mathematical
function describing glucose levels re-
corded across each measurement epi-
sode, hence its name “functional data
analysis” (FDA) (30).
Multivariable Statistical Analysis
Multivariable regression analysis was
used to establish the relationship be-
tween maternal glucose levels and LGA
for each of the summary statistical in-
dices and for the FDA-generated glucose
function, after adjusting for potential
confounders. A directed acyclic graph
(DAG) (31; see Supplementary Data) es-
tablished that it was necessary to adjust
for two covariates as potential con-
founders (type of diabetes and study
center), the latter to address the poten-
tial impact of differences in the conduct
of each of the original trials (particularly
different sensor types, different numbers
of observations per participant, and dif-
ferent intensities of assessment). None of
the remaining covariates (age at onset of
diabetes, maternal BMI, and insulin regi-
men) required adjustment because all fell
on the causal pathwaybetween type of
diabetes and LGA. Separate regression
models were ﬁtted for data from mea-
surement episodes within each trimester
of pregnancy to explore trimester-speciﬁc
relationships between glucose levels
and LGA. All statistical analyses were
conducted in R (32) and Stata (33).
Ethics
All participants provided written in-
formed consent. Ethical approval was
granted by the Suffolk and Norfolk Local
Research Ethics Committee and the
Danish National Committee on Biomed-
ical Research Ethics.
RESULTS
Table 1 shows the number of women
and the measurements made from the
original studies. CGM data were avail-
able for 132 women. Of these, 15 (11%)
were not included because their CGM
monitors had not generated mea-
surements for at least one full 24-h pe-
riod (n = 10), their pregnancy had
resulted in twins (n = 2), or the infant’s
birth weight had not been recorded (n =
3). After excluding these participants, data
from 117 singleton pregnancies, compris-
ing 1.68 million glucose measurements
conducted over 759 separate measure-
ment episodes, were available for the
analyses that follow. Of these 117
women, 95 (81%) had measurement ep-
isodes in trimester 1, 96 (82%) in trimes-
ter 2, and 80 (68%) in trimester 3; 89
(76%) had type 1 diabetes and 28
(24%) had type 2 diabetes; and 54
(46%) delivered an infant with LGA
and 63 (54%) delivered infants who
did not have LGA. Mean HbA1c levels
(45 mmol/mol) during pregnancy indi-
cated that these diabetic pregnancies
were clinically well controlled, and there
was no signiﬁcant difference in mean
HbA1c levels among mothers with LGA in-
fants (46 mmol/mol [95% CI 44–48]) and
Table 1—Number of women available in the analysis and number of measurements
in the study
England Denmark Total
Number of women in analysis
Eligible 61 71 132
Excluded 12 3 15
Included 49 68 117
Type 1 diabetes 35 54 89
Type 2 diabetes 14 14 28
Trimester 1 31 64 95
Trimester 2 44 52 96
Trimester 3 30 50 80
LGA infant 23/49 (46.9%) 31/68 (45.6%) 54/117 (46.1%)
Number of measurements 256,640 1,423,706 1,680,346
Number of measurement episodes 171 588 759
care.diabetesjournals.org Law and Associates 1321
those without LGA infants (44 mmol/mol
[42–46]; P = 0.794).
Summary Statistical Analysis
The summary statistical indices of CGM
data recorded in each trimester, calcu-
lated separately for women who deliv-
ered LGA versus non-LGA infants after
adjustment for confounders (type of di-
abetes and study), are presented in Ta-
ble 2. There were statistically signiﬁcant
differences in the values of all but six of
these indices (proportion of time below
target, area under the curve ,3.5 and
,2.8 mmol/L, ADDR RLBG and RHBG,
andMAGE2) amongwomenwith/without
LGA infants. However, the indices display-
ing signiﬁcant differences varied from one
trimester to thenext, as did themagnitude
and direction of the differences observed.
In trimester 1, LGA was associated with a
signiﬁcantly lower mean glucose, a lower
SD of mean glucose, a lower LI, a lower
J-index, and a lower MAGE+. In contrast,
in trimester 2, a higher mean glucose, a
higher percentage of time spent above
target (and less time within target), a
greater area under the curve for both
.7.8 and .6.7 mmol/L, a higher
M-value, a higher GRADE, and a higher
MAG were all signiﬁcantly associated
with LGA. In trimester 3, LGA was as-
sociated with a signiﬁcantly higher
mean glucose and a signiﬁcantly
higher LI.
FDA
Figure 1 summarizes the differences in
glucose levels observed throughout the
24-h day in women with LGA infants (as
compared with women who did not
have LGA infants) after applying FDA to
CGM data from each trimester, and af-
ter adjustment for confounders (type of
diabetes and study center). In each tri-
mester, mothers who delivered LGA in-
fants displayed signiﬁcantly different
glucose levels than those displayed by
mothers who did not deliver LGA in-
fants. However, the timing, duration,
magnitude, and direction of these dif-
ferences varied from one trimester to
the next. In trimester 1, mothers who
delivered LGA infants had signiﬁcantly
lower glucose levels from 0855 to 1105
h and from 1915 to 2135 h. In trimester
2, mothers who delivered LGA infants
had glucose levels that were higher
throughout both day and night and
were signiﬁcantly so for much of the
afternoon (from 1125 to 1710 h) and
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the early hours of the morning (from
0330 to 0635 h). In trimester 3, glucose
levels were again higher throughout
much of the day and night (and signiﬁ-
cantly so from 2035 to 2325 h), but there
was also a short period in the late after-
noon from 1705 to 1745 h where glucose
levels were signiﬁcantly lower among
women who delivered LGA infants.
CONCLUSIONS
Using comprehensive standard sum-
mary statistical analyses of CGM data,
this is the ﬁrst study of well-controlled
diabetic pregnancies to demonstrate
that 1) lower, and less variable, glucose
levels in the ﬁrst trimester of pregnancy
are signiﬁcantly associated with LGA; 2)
higher, andmore variable, glucose levels
in both the second and third trimester
are associated with LGA; and 3) FDA can
be applied to CGM data to expose the
temporal glucose proﬁles underlying
these associations and the key contribu-
tion that relatively short-term glucose
excursions during the 24-h period play
therein. These temporal proﬁles indi-
cate that the lower average glucose lev-
els associated with LGA in the ﬁrst
trimester (Table 2) are driven by distinct
dips in glucose levels midmorning and
midevening (Fig. 1), whereas the higher
average glucose levels associated with
LGA in the second and third trimester
(Table 2) are driven by signiﬁcantly
higher glucose levels that occur during
the early hours of themorning and after-
noon in the second trimester and during
the late evening in the third trimester
(Fig. 1). The magnitude of the transient
excursions detected by FDA of CGM data
are also substantively larger (in mmol/L)
than the differences in summary statisti-
cal indices of average glucose levels and
glucose variability, suggesting that FDA
of CGM data might offer more sensitive
information for use in the clinical man-
agement of glucose control in diabetic
pregnancy.
Poor glycemic control assessed by
HbA1c both before and during preg-
nancy has long been associated with ac-
celerated fetal growth, particularly
when HbA1c is elevated during the third
trimester (4,16,34–36). However, even
when mothers and their clinicians
achieve tight glycemic targets with
near-normal HbA1c levels, LGA contin-
ues to be a considerable problem
(4,37). Our study conﬁrms that a sub-
stantial proportion of diabetic preg-
nancies (in this instance .46%) result
in the delivery of LGA infants, even
when these pregnancies achieve rea-
sonable control based on mean HbA1c
values. Given that HbA1c measure-
ments provide a retrospective measure
of averaged glucose levels, they are
less likely to be able to detect
shorter-term variation in glucose levels
that might be relevant in the develop-
ment of LGA.
It is interesting that relatively lower
glucose proﬁles during the ﬁrst trimes-
ter are associated with subsequent LGA,
given that clinical practice has been
based on the understanding that tight
glucose control in the ﬁrst trimester is
beneﬁcial and does not have any ad-
verse fetal repercussions. We postulate
that the lower glucose we observe dur-
ing the ﬁrst trimester allows for the
development of a healthier fetoplacental
unit that subsequently allows more efﬁ-
cient transfer of nutrients to the fetus later
in pregnancy, enhancing the prospect of
LGA. This is supported by work showing
that fetal growth is determined in the ﬁrst
trimester (34) and that higher HbA1c in the
ﬁrst trimester is associated with lower
birth weight possibly due to impairment
of trophoblast implantation (38).
Our data supports ﬁndings from pre-
vious studies suggesting that relatively
higher glucose during the second tri-
mester contributes to LGA (37). Our
study adds to this however, by showing
that the time of day most signiﬁcantly
associated with higher glucose is
throughout the afternoon. A further pe-
riod of concern is in the early hours of
the morning. This may reﬂect a ten-
dency for the pregnant woman and her
clinical team to relax slightly after the
woman gets past the initial 12 weeks
knowing organogenesis is now com-
plete. It may also represent a gradual
increase in insulin resistance and a fail-
ure to keep on top of this with increasing
insulin doses.
The signiﬁcant difference in glucose
proﬁle in the third trimester focuses
our attention on the contribution
that a relatively lower glucose late after-
noon, followed by a higher glucose dur-
ing the evening and ﬁrst part of the
night, has on the association between
glucose levels and LGA. Based on previ-
ous work, we hypothesize that this re-
ﬂects changes in insulin responsiveness
at this stage in pregnancy (39). Whereas
there are no changes in glucose bio-
availability or postprandial glucose
Figure 1—Difference in glucose levels between non-LGA (represented by the horizontal zero level) and LGA (dark line) with 95% pointwise CIs (gray
section) (signiﬁcant differences, using 95% CIs, are highlighted by *) stratiﬁed by trimester from the regressionmodel (adjusted for study and type of
diabetes). Dashed vertical lines represent 0700 h and 2300 h.
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appearance between early and late ges-
tation in type 1 diabetic pregnancy, there
are signiﬁcant delays in postprandial glu-
cose disposal during late gestation, possi-
bly due to a combination of increased
peripheral insulin resistance, and a slower
achievement of a maximal postprandial
insulin concentration, facilitating more
prolonged postprandial hyperglycemia
in late pregnancy (39). Getting women
to bolus their insulin up to 40 min before
their evening meal may help avoid this
phenomenon. An alternative would be
to advise women to replace rapidly ab-
sorbed carbohydrate-rich meals for
more slowly absorbedunreﬁned carbohy-
drates or to consider premeal snack pri-
mers (40) or postprandial physical activity
to enhance peripheral glucose uptake.
CGM offers a potential source of data
required to improve the detection and
management of glucose levels in dia-
betic pregnancy. CGM provides far
more frequent glucose measurements
than SMBG and far more information
on short-to-medium-term trends in glu-
cose levels than either SMBG or HbA1c.
CGM is also capable of recording glucose
levels throughout both day and night
without disrupting the normal activities
of daily living (particularly periods of ac-
tivity, rest, and sleep). However, one
hitherto unresolved challenge has
been how the detailed and complex
data that CGM provides might best be
interpreted. A recent call to standardize
the reporting of CGM data recorded
during pregnancy (17) proposed
using a number of summary statistical
indices. This was supported by previous
research on nondiabetic obese and nor-
mal weight pregnancies (41), which
found that higher average glucose lev-
els during the third trimester were as-
sociated with neonatal adiposity,
suggesting that elevated glucose levels
in women exhibiting normal glucose
tolerance might contribute to excess
fat accumulation by the fetus. Re-
search on 29 pregnant women with
type 1 diabetes using statistical sum-
mary indices of CGM data (37) found
an association between higher average
daily glucose levels in each trimester
and babies diagnosed as extremely
LGA detected by ultrasound scan be-
fore 30 weeks gestation. However,
the signiﬁcant association between
HbA1c and birth weight in that study
(37) suggests that these diabetic
pregnancies could be detected without
detailed analysis of CGM.
By identifying, for the very ﬁrst time,
distinct temporal patterns of glucose
across the 24-h day that were associated
with LGA, our analyses demonstrate
how FDA of CGM data might enable us
to more precisely identify the speciﬁc
time points at which differences in aver-
age glucose and/or glucose variability
might contribute to excessive fetal
growthwithin each trimester. This infor-
mation is hidden within conventional
clinical interpretations of CGM data
and is not evident from any of the sum-
mary statistical indices we applied. The
temporal patterns revealed by FDA tell
us that short-term differences in glucose
levels underlie the signiﬁcant differ-
ences in summary statistical indices of
average glucose levels and glucose var-
iability across each trimester. As such,
FDA of CGM data allows us to better
understand where, when, and how we
might better invest our efforts to opti-
mize glucose control in diabetic preg-
nancy to reduce LGA and improve
pregnancy outcomes.
Limitations of the Study
We recognize that in common with
many monitoring systems, CGM has lim-
itations, particularly with regard to the
quality of glucose readings during rapid
blood glucose changes and in situations
of hypoglycemia. The measurement of
interstitial glucose may also not reﬂect
precisely the levels of blood glucose.
However, frequent calibration of the
CGM using SMBG levels helps partly to
resolve this issue. It is worth noting that
we have not corrected for multiple test-
ing and therefore there is the possibility
of a type 1 statistical error in the analy-
ses we present. There are also a number
of limitations in relation to the sample of
participants. The women in the study
were predominantly of white European
ethnicity, which may limit applicability
to women from other cultures and back-
grounds. The results do not include any
women with gestational diabetes, and
again care needs to be taken with regard
to its applicability in relating to LGA in
this context. All the women had conven-
tionally good glycemic control, judged
by capillary blood glucose targets and
HbA1c. This means that our ﬁndings can-
not be generalized to women with
known poor glycemic control. Further
work in this area is recommended as
conﬁdence in the observed associations
would be strengthened by validation in
an independent cohort.
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